{"filings":[{"id":2467716,"accession_number":"0001193125-26-365271","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2026-08-25T20:51:00+00:00","items":["5.02","9.01"],"status":"ready","headline":"Core Laboratories director Kwaku Temeng resigns Oct 1 over strategy, governance disagreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kwaku Temeng resigns as director effective Oct 1, 2026; cites disagreement over strategic direction and governance.","He served as Chairman of Nominating Committee and member of Compensation Committee.","Board says primary disagreement concerns succession planning approach; Temeng also has research-priority concerns.","Resignation letter filed as Exhibit 17.1; no replacement director announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1942078,"accession_number":"0001193125-26-324101","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2026-07-29T20:43:31+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Labs Q2 revenue $124.6M, down 4% YoY; EPS ex-items $0.11, down 42% YoY; declares $0.01 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $124.6M, up 2% sequentially but down 4% YoY; GAAP EPS $0.13, ex-items EPS $0.11.","Operating income ex-items $9.4M, up 42% sequentially but down 36% YoY; operating margin 8%.","Free cash flow $3.1M; repurchased 214,712 shares for $2.7M.","Declared Q3 2026 dividend of $0.01/share, payable Aug 31 to holders of record Aug 10."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":70081,"accession_number":"0001193125-26-221857","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2026-05-13T20:54:51+00:00","items":["5.07"],"status":"ready","headline":"Core Labs shareholders re-elect directors, ratify auditor, approve say-on-pay at May 12 meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-elected Harvey Klingensmith (35.9M for, 3.8M withheld) and Curtis Anastasio (39.3M for, 0.4M withheld) as Class I directors.","Ratified KPMG as independent auditor for FY 2026 with 41.2M for, 0.5M against.","Advisory vote on named executive officer compensation approved: 38.3M for, 1.3M against, 0.1M abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96922,"accession_number":"0001193125-26-192018","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Lab Q1 revenue $121.8M; GAAP EPS -$0.02, ex-items $0.06","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $121.8M, down 12% sequentially and flat year-over-year.","GAAP operating income $1.9M; ex-items $6.6M, down 58% sequentially.","GAAP loss per share $0.02; EPS ex-items $0.06, down 72% sequentially and 58% YoY.","Free cash flow $0.5M; net debt up $3.9M; leverage ratio 1.20.","Q2 dividend $0.01/sh, record May 11, payable June 1; repurchased 51,781 shares for $0.9M."],"consensus_eps_estimate":0.1094,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":121797000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111293,"accession_number":"0001193125-26-119934","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Core Labs cuts Q1 2026 guidance citing Middle East conflict; revenue now $119-123M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First quarter 2026 revenue guidance revised to $119M-$123M, down from previously issued guidance.","Operating income ex-items projected at $5.7M-$7.1M; EPS ex-items $0.05-$0.07.","Client-driven project delays, travel constraints, and supply-chain disruptions from Middle East conflict cited.","Reservoir Description segment most impacted; Production Enhancement less affected but energetics shipments delayed.","Earnings call scheduled for April 30, 2026; press release on April 29 after market close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111290,"accession_number":"0001193125-26-109251","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K/A","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Core Laboratories corrects Q4/FY2025 tax error; net income down $4.2M, EPS down $0.09","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Income tax expense understated by $4.2M in Q4 and FY2025 due to tax reconciliation and fire-related insurance gain timing.","Net income reduced by $4.2M; diluted EPS reduced by $0.09 for both Q4 and full year 2025.","Revenue, operating income, and cash from operations unchanged.","Also corrected immaterial 2024 balance sheet errors: $4.7M misclassification and $5.6M write-off of unrecoverable tax receivable.","Revised financials expected in 10-K filing on or around March 17, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111292,"accession_number":"0001193125-26-093962","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Core Laboratories lowers shareholder voting threshold to simple majority for mergers and change-in-control","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amendment reducing supermajority voting requirement from 66-2/3% to simple majority for certain shareholder actions including mergers and change-in-control.","Amendment effective February 27, 2026; affects Section 2.11 of the First Amended and Restated Bylaws.","Only change in the amended bylaws; no other governance provisions modified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111291,"accession_number":"0001193125-26-037789","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Lab Q4 rev $138.3M (+7% YoY); ex-items EPS $0.21 (-4%); declares $0.01 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $138.3M (+7% YoY); GAAP EPS $0.15, ex-items $0.21 (-4% YoY).","Q4 op. income ex-items $15.7M (11% margin, -80bps YoY); free cash flow $5.1M.","FY 2025 revenue $526.5M (flat); GAAP EPS $0.68 (+3%), ex-items $0.75 (-14%).","Net debt reduced $18.7M in 2025 (17%); leverage ratio improved to 1.09x.","Declared Q1 2026 dividend $0.01/sh, payable Mar 9, record Feb 16; repurchased 1.2M shares."],"consensus_eps_estimate":0.1906,"consensus_eps_actual":0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":526520000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127901,"accession_number":"0001193125-25-246793","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Labs Q3 rev $134.5M flat YoY; ex-items EPS $0.22, down 12% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $134.5M, up 3% sequentially but flat YoY.","GAAP EPS $0.30; ex-items EPS $0.22 (+16% seq, -12% YoY).","Ex-items operating margins 12%, up 120 bps seq; incremental margins 48%.","Repurchased 462,248 shares for $5.0M; net debt reduced $3.4M; leverage 1.10x.","Quarterly dividend $0.01/sh, record Nov 3, payable Nov 24."],"consensus_eps_estimate":0.1949,"consensus_eps_actual":0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":388265000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144671,"accession_number":"0000950170-25-097897","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["1.01","2.02","2.03","7.01","9.01"],"status":"ready","headline":"Core Lab Q2 rev $130.2M (+5% seq, flat YoY); ex-items EPS $0.19; free cash flow $10.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $130.2M (+5% sequentially, flat YoY); GAAP EPS $0.22; ex-items EPS $0.19 (-14% YoY, +33% sequentially).","Ex-items operating income $14.5M, margins 11% (+160 bps seq); incremental margins 41%.","Free cash flow $10.4M (+160% seq); net debt reduced $9.1M; leverage ratio improved to 1.27x.","Company repurchased 237,632 shares for $2.7M in Q2.","Credit facility amended: commitments raised to $150M from $135M, maturity extended to July 2029, $50M accordion."],"consensus_eps_estimate":0.1906,"consensus_eps_actual":0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":253744000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163069,"accession_number":"0000950170-25-077738","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Core Labs elects three Class II directors, ratifies KPMG, approves say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Martha Z. Carnes, Katherine Murray, and Rob Martinovich as Class II directors to serve until 2028.","Ratified KPMG as independent auditor for 2025 with 41.8M votes for, 0.7M against.","Advisory vote on executive compensation approved with 38.0M for, 2.3M against, 26.5K abstentions.","All proposals passed with required majorities; broker non-votes were 2.18M on director and say-on-pay items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163068,"accession_number":"0000950170-25-057483","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Labs Q1 rev $123.6M, ex-items EPS $0.14 down 25% YoY, declares $0.01 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $123.6M, down 4% sequentially and 5% YoY; GAAP EPS $0.00, ex-items EPS $0.14 (down 25% YoY).","Operating income ex-items $11.8M, margins 10%; free cash flow $3.9M, up >50% YoY.","Net debt reduced $4.9M, leverage ratio 1.31; repurchased 131,598 shares for $2.0M.","Declares $0.01 quarterly dividend, record May 5, payable May 27."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":123585000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180979,"accession_number":"0000950170-25-010552","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Lab Q4 revenue $129.2M, EPS $0.15; FY revenue $523.8M up 3%, free cash flow $43.4M up 200%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $129.2M (down 4% sequentially, up slightly YoY); GAAP EPS $0.15; ex-items EPS $0.22 (down 12% sequentially, up 16% YoY).","Q4 operating income ex-items $15.7M (down 14% sequentially, up 4% YoY) with margins of 12%.","Q4 free cash flow $16.2M (up over 50% sequentially); net debt reduced $11.7M; leverage ratio 1.31.","FY 2024 revenue $523.8M (up 3%); ex-items operating income $65.3M (up 7%); ex-items EPS $0.87 (up 9%).","Company repurchased 264,982 shares for $4.9M in Q4; declared $0.01/share dividend payable March 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":523848000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197853,"accession_number":"0000950170-24-116676","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Lab Q3 revenue $134.4M +7% YoY; EPS ex-items $0.25 +14% YoY; net debt reduced","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $134.4M, up 3% sequentially and over 7% year-over-year.","Operating income ex-items $18.2M, up 11% sequentially and 14% YoY; margins 14%.","GAAP EPS $0.25; ex-items $0.25, up 14% sequentially and YoY.","Free cash flow $10.4M; net debt reduced $11.8M; debt leverage ratio 1.47.","Declares Q4 dividend $0.01/share, payable Nov 25 to holders of record Nov 4."],"consensus_eps_estimate":null,"consensus_eps_actual":0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":394611000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214038,"accession_number":"0000950170-24-086092","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Labs Q2 revenue $130.6M; GAAP EPS $0.19, ex-items $0.22; cuts net debt $15.8M; declares $0.01 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $130.6M, up slightly sequentially and YoY; operating income GAAP $16.0M, ex-items $16.4M (+10% sequentially, +5% YoY).","GAAP EPS $0.19; ex-items EPS $0.22, up 16% sequentially and 5% YoY.","Free cash flow $14.3M; net debt reduced by $15.8M during Q2 2024.","Declares Q3 2024 dividend of $0.01/share, payable Aug 26, record Aug 5, 2024.","Operating margins ex-items reached 13%, expanding over 100 bps sequentially."],"consensus_eps_estimate":null,"consensus_eps_actual":0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":260214000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233258,"accession_number":"0000950170-24-057934","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Annual meeting results: all four proposals approved by shareholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class III directors Lawrence Bruno and Kwaku Temeng re-elected with 37.4M and 33.0M votes for respectively.","Ratification of KPMG as auditor for FY2024 approved: 40.4M for, 0.8M against.","Advisory vote on executive compensation passed: 36.4M for, 1.8M against.","Amendment to 2020 Long-Term Incentive Plan (increase shares, extend to 2034) approved: 36.7M for, 1.5M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233257,"accession_number":"0000950170-24-047646","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Laboratories Q1 2024: Revenue $129.6M, EPS ex-items $0.19; declares $0.01 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $129.6M, up modestly sequentially and YoY.","GAAP operating income $8.6M; ex-items $14.9M, up 3% YoY.","GAAP EPS $0.07; ex-items $0.19, flat YoY.","Free cash flow $2.5M in Q1.","Declares $0.01 dividend payable May 28, record May 6."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":129637000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251383,"accession_number":"0000950170-24-035962","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Core Laboratories appoints Sow Hang Teo as VP & CAO after Kevin Daniels resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin Daniels resigned as VP & Chief Accounting Officer effective March 21, 2024; departure not due to dispute over accounting practices or financials.","Sow Hang Teo appointed as VP & Chief Accounting Officer same date; previously Corporate Controller of Financial Reporting since September 2017.","Teo has been with Core Labs since 2006, holds CPA (Malaysia) and MBA; no reportable transactions under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251381,"accession_number":"0000950170-24-015482","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K/A","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Core Laboratories amends Q4 2023 results; net income cut by $4.3M on tax error","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 GAAP net income restated to $2.2M from $6.5M; diluted EPS revised to $0.05 from $0.14.","FY 2023 GAAP net income restated to $36.7M from $40.9M; diluted EPS revised to $0.77 from $0.86.","Understated income tax expense of $4.3M in Q4 due to reassessment of foreign tax credits after redomestication.","Revenue, operating income, and cash from operations unchanged; ROIC revised from 13.4% to 12.0%.","Management reaffirms Q1 2024 effective tax rate guidance of 20%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":509790000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251382,"accession_number":"0000950170-24-009489","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Lab Q4 revenue $128.2M (+2% seq); EPS ex-items $0.19 (-14% seq); FY EPS +40%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $128.2M (+2% sequentially); GAAP EPS $0.14, ex-items EPS $0.19 (down 14% seq).","Q4 operating income ex-items $15.0M (12% margins); free cash flow $16.7M; debt cut $15M (8%).","Full year revenue $510.0M (+4% YoY); operating income ex-items $61.2M (+36%); EPS ex-items $0.80 (+40%).","Quarterly cash dividend $0.01/share, record Feb 12, payable Mar 4, 2024.","Effective tax rate impacted by non-cash deferred tax adjustments from U.S. domestication."],"consensus_eps_estimate":null,"consensus_eps_actual":0.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":509790000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268937,"accession_number":"0000950170-23-057543","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Lab Q3 revenue $125.3M, EPS $0.19 GAAP ($0.22 ex-items); $0.01 dividend; Halliburton alliance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $125.3M, down 2% sequentially, flat YoY; GAAP EPS $0.19, ex-items $0.22 (up 5% sequentially, 24% YoY).","Operating income ex-items $16.0M, operating margins 13%; Reservoir Description margins 17% with incremental margins >100% sequentially.","Announced strategic digital rock characterization alliance with Halliburton.","Declared Q4 dividend $0.01/share, record Nov 13, payable Dec 4.","Recorded $1.1M charges for ATM termination and facility exit included in GAAP results."],"consensus_eps_estimate":null,"consensus_eps_actual":0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":381580000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286036,"accession_number":"0000950170-23-034753","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Core Labs Q2 revenue $127.9M (+6% YoY); adj EPS $0.21 (+80% YoY); declares $0.01 dividend","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $127.9M, flat QoQ, up 6% YoY; GAAP EPS $0.48 (incl. $11.6M tax benefit and $2.9M gains).","Ex-items op income $15.6M (>12% margin), up 8% QoQ; ex-items EPS $0.21, up 80% YoY.","Free cash flow $6.6M; ATM equity program terminated.","Quarterly dividend $0.01/share, payable Aug 28 to holders of record Aug 7.","Reservoir Description incremental margins ex-items >100% QoQ and >80% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":256237000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286035,"accession_number":"0000950170-23-033405","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2023-07-18T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Core Laboratories terminates $60M ATM program; no shares sold under agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Equity Distribution Agreement dated June 9, 2022 with Wells Fargo and BofA.","Program authorized up to $60M in 'at the market' common stock offerings; zero shares were ever sold.","Termination effective July 17, 2023; no future sales under this program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286034,"accession_number":"0000950170-23-031189","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2023-07-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Core Labs shareholders elect directors, approve KPMG, say-on-pay, director plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Harvey Klingensmith and Curtis Anastasio elected as Class I directors with 33.6M and 37.3M votes for, respectively.","Ratification of KPMG as auditor approved: 40.5M for, 62.5K abstain.","Advisory vote on executive compensation approved: 36.2M for, 1.3M against.","Shareholders selected 1-year frequency for say-on-pay votes (35.9M votes for 1 year).","Director Plan amendment extending term to 2033 approved: 36.3M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305907,"accession_number":"0000950170-23-018053","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Core Labs issues $50M in senior secured notes at 7.25%-7.50% to refinance debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$25M of 7.25% notes due 2028 and $25M of 7.50% notes due 2030 placed privately.","Net proceeds to pay down existing credit facility and toward 2011 Senior Notes due Sept 2023.","Notes are senior secured, rank pari passu with existing senior debt; covenants include coverage and leverage ratios.","Closing expected on or about June 28, 2023; interest payable semi-annually starting Sept 28, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305906,"accession_number":"0001193125-23-130765","cik":1958086,"company_name":"Core Laboratories Inc. /DE/","ticker":"CLB","form_type":"8-K12B","filed_at":"2023-05-01T23:59:59+00:00","items":["1.01","2.01","2.03","3.01","3.03","5.03","5.01","5.02","9.01"],"status":"ready","headline":"Core Laboratories completes redomestication from Netherlands to Delaware as Core Laboratories Inc.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective May 1, 2023, Core Lab N.V. merged into Core Lab Luxembourg and then redomesticated as Core Laboratories Inc. (Delaware).","All common shares converted 1:1; same directors, officers, and business continue under Delaware corporation.","Core Lab Delaware assumed all obligations under existing credit facility and senior notes (2011 and 2021 issuances).","Common stock continues trading on NYSE under symbol CLB; new CUSIP 21867A 105.","Corporate governance changes from two-tier board to single board; certificate and bylaws filed as Exhibits 3.1 and 3.2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":643048756.0485021,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}